Loading stock data…
Bioventus Inc. (BVS)
$9.78
Market ClosedLast close Jun 29
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bioventus Inc. in the Healthcare sector is trading at $9.78 with a market capitalization of $579M. Wall Street consensus targets $14.80 (5 analysts), implying a +51.3% move over the next 12 months. The stock is currently 13% below its 52-week high of $11.25, remaining 18.4% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +51.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $132.09M↓ | $157.90M↑ | $138.65M↓ | $147.66M↑ | $123.88M |
| Gross Profit | $90.77M↓ | $108.78M↑ | $94.23M↓ | $102.09M↑ | $83.06M |
| Operating Income | $8.87M↓ | $21.72M↑ | $11.25M↓ | $18.37M↑ | $4.95M |
| Net Income | $3.11M↓ | $14.76M↑ | $3.15M↓ | $7.46M↑ | -$2.64M |
Peer Comparison
JNJUNHPFE
Fundamentals
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$579.25M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.85
Beta
Defensive asset. Lower volatility than the S&P 500.
0.72
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.08%
Volume
Today's trading volume
571,218
Recent News
Should Value Investors Buy Bioventus (BVS) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Medical Stocks Lagging BrightSpring Health Services, Inc. (BTSG) This Year?
Here is how BrightSpring Health Services, Inc. (BTSG) and Bioventus (BVS) have performed compared to their sector so far this year.
Are Investors Undervaluing Bioventus (BVS) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bioventus Highlights PNS, PRP Growth as Cash Flow Improves and Debt Falls
Bioventus (NASDAQ:BVS) executives outlined the company’s portfolio strategy, growth priorities and capital allocation plans during a Goldman Sachs event hosted by Jenny Rabinowitz, an analyst covering U.S. medtech and healthcare IT. Mark Singleton, Bioventus’ senior vice president and chief financi
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
Here is how Allarity Therapeutics, Inc. (ALLR) and Bioventus (BVS) have performed compared to their sector so far this year.